CEDAR: A Phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer
- Honorary Consultant Clinical Oncologist, Oxford University Hospitals NHS Trust
The aim of my research is to develop new radiotherapy treatments to maximise clinical benefit in terms of better tumour control and reduction in toxicity. The novel radiotherapy will, if successful, change routine clinical practice in high priority cancers through funded NIHR portfolio trials.
Maria is a clinician scientist in precision radiotherapy committed to improving outcome through high quality research leading MRC funded Advanced Radiotherapy Group in the MRC Oxford Institute for Radiation Oncology. She is also an Honorary Consultant Clinical Oncologist at the Oxford University Hospitals NHS Trust since 2013.
She is the chief investigator of 4 CRUK funded trials including radiation novel agents combination in phase I, but in radical setting (ATR-i with chemoradiation in the definitive setting for oesophageal cancer or combining adenovirus and chemoradiation in the pre-operative setting of rectal cancer). MRC, CRUK and industry partners fund research.
She is the Clinical Chair of NCRI CTRad technical radiotherapy workstream and has 70 publications, invited speaker and faculty international meetings (NCRI, ASTRO, ASCO-GI, ESTRO, ECCO).
Holyoake DLP. et al, (2019), Radiother Oncol, 138, 38 - 44
Renehan AG. et al, (2019), Colorectal Dis, 21, 387 - 391
Strauss VY. et al, (2019), BMC Cancer, 19
Gwynne S. et al, (2019), Radiat Oncol, 14
Sabbagh A. et al, (2019), Clin Oncol (R Coll Radiol), 31, 72 - 80
2008 - Dr Karol Sicher Fellowship by RCR
2009 - Sylvia Lawler Prize, Oncology Section Royal Society of Medicine
2013 - Honorary Member of Association Belge de Radiothérapie-Oncologie
2018 - Honorary Fellow of the RCR Ireland